Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas.

Nachnani JS, Bulchandani DG, Nookala A, Herndon B, Molteni A, Pandya P, Taylor R, Quinn T, Weide L, Alba LM

Diabetologia13 Sept 2009Cited by 155 (Europe PMC)

PMID19756486DOI10.1007/s00125-009-1515-4PepBankPUB-19756486

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Safety outcome
In rats, exendin‑4 increased pancreatic acinar inflammation compared with controls.
In plain wordsIn rats, exendin‑4 increased pancreatic inflammation compared with controls.
Peptide
Exenatide (exendin-4)
Outcome
IncreasePancreatic acinar inflammation
Study
ratn = 20
Male Sprague-Dawley rats
Comparator
Untreated control rats
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated · 75 daysAs given in this study (rat).
Source sentences
Summary
Animals treated with exendin-4 had more pancreatic acinar inflammation, more pyknotic nuclei and weighed significantly less than control rats.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied 20 Sprague-Dawley male rats, ten of which were treated with exendin-4 and ten of which were used as controls. The study period was 75 days.
Report a problemFND-1975648601
02AnimalAnimal study (in vivo)Safety outcome
In rats, exendin‑4 increased pancreatic pyknotic nuclei compared with controls.
In plain wordsIn rats, exendin‑4 increased shrunken cell nuclei in the pancreas compared with controls.
Peptide
Exenatide (exendin-4)
Outcome
IncreasePyknotic nuclei
Study
ratn = 20
Male Sprague-Dawley rats
Comparator
Untreated control rats
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated · 75 daysAs given in this study (rat).
Source sentences
Summary
Animals treated with exendin-4 had more pancreatic acinar inflammation, more pyknotic nuclei and weighed significantly less than control rats.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied 20 Sprague-Dawley male rats, ten of which were treated with exendin-4 and ten of which were used as controls. The study period was 75 days.
Report a problemFND-1975648602
03AnimalAnimal study (in vivo)Efficacy outcome
In rats, exendin‑4 reduced body weight compared with controls.
In plain wordsIn rats, exendin‑4 reduced body weight compared with controls.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
ratn = 20
Male Sprague-Dawley rats
Comparator
Untreated control rats
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 75 daysAs given in this study (rat).
Source sentences
Summary
Animals treated with exendin-4 had more pancreatic acinar inflammation, more pyknotic nuclei and weighed significantly less than control rats.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied 20 Sprague-Dawley male rats, ten of which were treated with exendin-4 and ten of which were used as controls. The study period was 75 days.
Report a problemFND-1975648603
04AnimalAnimal study (in vivo)Safety outcome
In rats, exendin‑4 increased serum lipase compared with controls.
In plain wordsIn rats, exendin‑4 increased blood lipase compared with controls.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSerum lipase
Study
ratn = 20
Male Sprague-Dawley rats
Comparator
Untreated control rats
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated · 75 daysAs given in this study (rat).
Source sentences
Summary
They also had higher serum lipase than control animals.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied 20 Sprague-Dawley male rats, ten of which were treated with exendin-4 and ten of which were used as controls. The study period was 75 days.
Report a problemFND-1975648604
05AnimalAnimal study (in vivo)Efficacy outcome
In rats, exendin‑4 reduced insulin levels compared with untreated controls.
In plain wordsIn rats, exendin‑4 reduced insulin levels compared with untreated controls.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseInsulin
Study
ratn = 20
Male Sprague-Dawley rats
Comparator
Untreated control rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 75 daysAs given in this study (rat).
Source sentences
Summary
Exendin-4 treatment was associated with lower insulin and leptin levels as well as lower HOMA values than in the untreated control group.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied 20 Sprague-Dawley male rats, ten of which were treated with exendin-4 and ten of which were used as controls. The study period was 75 days.
Report a problemFND-1975648605
06AnimalAnimal study (in vivo)Efficacy outcome
In rats, exendin‑4 reduced leptin levels compared with untreated controls.
In plain wordsIn rats, exendin‑4 reduced leptin levels compared with untreated controls.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseLeptin
Study
ratn = 20
Male Sprague-Dawley rats
Comparator
Untreated control rats
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · 75 daysAs given in this study (rat).
Source sentences
Summary
Exendin-4 treatment was associated with lower insulin and leptin levels as well as lower HOMA values than in the untreated control group.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied 20 Sprague-Dawley male rats, ten of which were treated with exendin-4 and ten of which were used as controls. The study period was 75 days.
Report a problemFND-1975648606
07AnimalAnimal study (in vivo)Efficacy outcome
In rats, exendin‑4 reduced HOMA values compared with untreated controls.
In plain wordsIn rats, exendin‑4 reduced HOMA values compared with untreated controls.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHOMA
Study
ratn = 20
Male Sprague-Dawley rats
Comparator
Untreated control rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 75 daysAs given in this study (rat).
Source sentences
Summary
Exendin-4 treatment was associated with lower insulin and leptin levels as well as lower HOMA values than in the untreated control group.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied 20 Sprague-Dawley male rats, ten of which were treated with exendin-4 and ten of which were used as controls. The study period was 75 days.
Report a problemFND-1975648607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.